Foundation for Sarcoidosis Research (FSR) announces three clinics that have been selected as members of FSR Global Sarcoidosis Clinic Alliance (FSR-GSCA) – a groundbreaking initiative that will have a worldwide impact on advancing sarcoidosis research and improving...
Beginning September 16th, Walgreens, a pharmacy and retail leader who plays a critical role in the U.S. healthcare system by providing a wide range of pharmacy and healthcare services, including those that drive equitable access to care for the nation’s medically...
The Foundation for Sarcoidosis Research (FSR) is pleased to announce the appointment of Calvin Harris Jr., CPA and Joel D. Rosen, Esq. to the FSR Board of Directors. “We are thrilled to welcome Calvin and Joel to the FSR Board of Directors,” said Dr....
Recently, we asked our dedicated and generous Sarcoidosis Awareness Campaign Gold Level Sponsor, aTyr Pharma, Inc., to share more about their passion for raising awareness and improving the lives of those impacted by sarcoidosis. Check out how they are accelerating...
On April 21, 2022, The Foundation for Sarcoidosis Research (FSR) hosted a virtual Patient Listening Session on Pulmonary Sarcoidosis with the US Food and Drug Administration (FDA). FDA Patient Listening Sessions are small, informal, non-regulatory, non-public...
We are proud to announce that they have been selected as an awardee for the Chan Zuckerberg Initiative (CZI) Rare As One Cycle 2 grant which will provide $600,000 to improve diagnostics and increase research in sarcoidosis. This work is part of CZI’s Rare...
My journey with Interstitial Lung Disease (ILD) started about 15 years ago, although I did not know it at the time, nor did the physicians who were then treating me. At an annual physical, at the age of 46, I mentioned that my knees were a bit sore after physical...
Xentria Inc. has recently announced they received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for their intravenous TNF-inhibitor, XTMAB-16. The FDA grants orphan status to drugs being developed to treat those with rare diseases. This...
The following is an exciting announcement from an FSR partner, Boehringer Ingelheim – see the release on their website here. Boehringer Ingelheim Begins Phase 2 Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness from COVID-19...
FSR is a proud member of NORD, the National Organization for Rare Disorders. On April 15th, NORD announced the creation of a program to provide financial assistance for members of the rare disease community who have been impacted by COVID-19. Read the release below or...
